2 No-Brainer Stocks to Buy Before the End of 2024

As we approach the end of 2024, investors are looking for opportunities to grow their portfolios. Two stocks that stand out as no-brainer investments are BioNTech (BNTX) and Vertex Pharmaceuticals (VRTX). Both companies have promising pipelines and undervalued valuations, making them compelling choices for investors seeking growth and value.



BioNTech is a biotechnology company with a strong focus on cancer therapies. The company has four late-stage programs, two of which are cancer therapies, and 13 candidates in phase 2 testing, all targeting various types of cancer. BioNTech expects to launch its first cancer immunotherapy within the next two years and aims to win 10 indication approvals in oncology by 2030. Despite these promising prospects, BioNTech's enterprise value is around $11 billion, with an expected 2024 sales of at least $2.6 billion, resulting in a price-to-sales ratio of 4.2, well below the biotech industry average of 7.5. This undervalued valuation presents a significant opportunity for investors.

Vertex Pharmaceuticals is a pharmaceutical company with a diverse pipeline, including cystic fibrosis (CF) therapies, pain management, and kidney disease treatments. With a monopoly in CF treatment, Vertex's CF franchise is expected to generate billion-dollar earnings well into the next decade. The company's upcoming vanzacaftor triple-drug combo and suzetrigine for pain management, both with potential approvals in early 2025, further bolster its growth prospects. Additionally, Vertex's partnership with CRISPR Therapeutics on Casgevy and its work on a candidate to address pain, VX-548, showcase its commitment to innovation. Despite its strong growth prospects, Vertex trades at a reasonable valuation of 25 times forward earnings, making it an attractive investment opportunity.



In conclusion, BioNTech and Vertex Pharmaceuticals are two no-brainer stocks to consider before the end of 2024. Both companies have promising pipelines and undervalued valuations, making them compelling choices for investors seeking growth and value. As the market continues to evolve, these companies' strong fundamentals and growth prospects position them well for long-term success.